TL;DR:
- FOXO Technologies, a leader in epigenetic biomarker technology, receives significant patent recognition from the USPTO.
- The granted patent utilizes machine learning to determine medical conditions using DNA epigenetic data.
- The first patent allows filling in missing or unreliable epigenetic data using machine learning estimators.
- The second patent estimates various health aspects, from disease states to biomarker levels, using machine learning.
- FOXO Technologies aims to leverage these patents for AI-driven health insights, life insurance underwriting, clinical testing, and more.
- The company has collected epigenetic data from over 13,000 individuals to support these patents.
- FOXO Technologies’ CEO emphasizes their commitment to improving health and well-being through AI and epigenetics.
- The patents represent a milestone in combining biotechnology and AI for personalized healthcare.
Main AI News:
FOXO Technologies Inc., a frontrunner in the arena of commercializing epigenetic biomarker technology, has just received noteworthy recognition from the United States Patent & Trademark Office (USPTO). In a pivotal development, the USPTO has issued an Issue Notification for a pivotal patent, employing a cutting-edge machine learning model meticulously trained to ascertain biochemical states and medical conditions. This breakthrough patent is poised to revolutionize the commercialization of epigenetic biomarkers.
Earlier, FOXO Technologies had already garnered acclaim with Notices of Allowance for two closely related patents. Now, as the Issue Notification for the first allowed patent arrives, the company takes a significant stride toward realizing its mission.
The first patent in question facilitates practical applications of the technology, particularly in the realm of generating epigenetic biomarkers. At times, epigenetic data may be incomplete or unreliable due to unassayed DNA sites or erratic measurements. Enter FOXO’s innovative approach – the utilization of machine learning estimators to seamlessly “fill in” the gaps in epigenetic data at specific loci.
The second patent, which has received a Notice of Allowance, is a game-changer. It harnesses the power of machine learning to estimate various aspects of an individual’s health, encompassing disease states, biomarker levels, drug usage, health histories, and factors relevant to mortality risk assessment. The applications for this patent are multifaceted, spanning from an AI-powered platform delivering health insights to individuals and healthcare professionals to life insurance underwriting, clinical testing, and consumer health.
To fortify these patents, FOXO Technologies has meticulously curated epigenetic data from over 13,000 individuals through a blend of internal research initiatives and external collaborations. The integration of this expansive dataset with comprehensive phenotypic information is set to propel product development, as eloquently outlined in the company’s patent claims.
Mark White, serving as Interim CEO of FOXO Technologies, emphasized, “As pioneers in the realm of epigenetic biomarker discovery and commercialization, FOXO Technologies remains unwavering in its commitment to harnessing the synergies of epigenetics and artificial intelligence. Our goal is to furnish data-driven insights that foster optimal health and longevity, both for individuals and organizations. Our resolute dedication to enhancing the quality of life and promoting well-being places FOXO Technologies at the vanguard of biotechnological innovation, with a clear vision of harnessing AI to penetrate diverse commercial markets.”
The newly granted patent reaffirms FOXO Technologies’ position as a luminary at the intersection of biotechnology and artificial intelligence. It signifies a pivotal milestone in the company’s overarching mission – extending and enriching human life through advanced diagnostics, therapeutic solutions, and lifestyle modifications. Furthermore, by amalgamating the realms of epigenetics and artificial intelligence, FOXO Technologies pioneers a new era of personalized healthcare. This patent marks an epochal leap towards crafting innovative tools that empower individuals and healthcare professionals to make informed decisions regarding health and well-being.
Nichole Rigby, FOXO Technologies’ Director of Bioinformatics & Data Science, commented, “The bestowal of these patents underscores our unwavering commitment to pushing the boundaries, converging biotechnology and AI. We eagerly anticipate the transformative potential of this technology in the realm of health solutions, heralding an era of healthier and longer lives for all.”
Conclusion:
FOXO Technologies’ recent patent achievements signify a significant leap in the convergence of biotechnology and artificial intelligence. These patents empower the company to provide innovative, data-driven health solutions, extending beyond personalized healthcare into diverse commercial markets. FOXO Technologies’ pioneering work promises to revolutionize the industry and improve the quality of life for individuals and organizations alike.
